Codex DNA (NASDAQ:DNAY – Get Rating) released its quarterly earnings results on Wednesday. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.05, MarketWatch Earnings reports. Codex DNA had a negative return on equity of 43.84% and a negative net margin of 311.52%.
NASDAQ DNAY traded up $0.11 on Friday, reaching $3.81. The company had a trading volume of 120,067 shares, compared to its average volume of 205,757. Codex DNA has a fifty-two week low of $3.43 and a fifty-two week high of $25.70. The business has a 50 day moving average of $5.74 and a two-hundred day moving average of $7.35. The company has a debt-to-equity ratio of 0.16, a quick ratio of 9.33 and a current ratio of 9.57.
A number of institutional investors and hedge funds have recently modified their holdings of DNAY. Millennium Management LLC boosted its position in Codex DNA by 86.9% during the fourth quarter. Millennium Management LLC now owns 1,264,040 shares of the company’s stock valued at $13,652,000 after acquiring an additional 587,668 shares during the last quarter. BlackRock Inc. boosted its position in Codex DNA by 45.2% during the fourth quarter. BlackRock Inc. now owns 484,089 shares of the company’s stock valued at $5,229,000 after acquiring an additional 150,618 shares during the last quarter. State Street Corp boosted its position in shares of Codex DNA by 104.8% during the 4th quarter. State Street Corp now owns 146,710 shares of the company’s stock worth $1,584,000 after purchasing an additional 75,089 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Codex DNA by 421.8% during the 3rd quarter. Geode Capital Management LLC now owns 74,339 shares of the company’s stock worth $827,000 after purchasing an additional 60,091 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Codex DNA by 14.9% during the 1st quarter. Vanguard Group Inc. now owns 361,891 shares of the company’s stock worth $1,944,000 after purchasing an additional 46,974 shares in the last quarter. 87.58% of the stock is currently owned by institutional investors and hedge funds.
Codex DNA Company Profile (Get Rating)
Codex DNA, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.
- Get a free copy of the StockNews.com research report on Codex DNA (DNAY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Codex DNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codex DNA and related companies with MarketBeat.com's FREE daily email newsletter.